Profibrix

Home About ProFibrix Profile Leadership Supervisory Board News & Investment Info The Market Publications Fibrocaps™ Clinical Development Manufacturing Delivery Device Recombinant Fibrinogen Contact Us Natural fibrinogen building blocks form the basis of all our products.
	Inspired by Nature, with Science as our Tool, we create Innovative Healthcare Products. ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field of hemostasis. Fibrocaps™, the proposed name of the company’s lead biologic, is being studied to help stop bleeding during surgery and after trauma injury. A dry powder based on a mixture of fibrinogen and thrombin, Fibrocaps is a ready-to-use preparation designed to be stable at room temperature and applied in different formats, including sprays and bandages.	ProFibrix News Press Release ProFibrix to Present Phase II Data at International Fibrinogen Workshop in Rotterdam, The Netherlands - LEIDEN & ROTTERDAM, THE NETHERLANDS, August 23, 2010 - more> Press Release ProFibrix and CSL Behring Enter into Fibrinogen and Thrombin Supply Agreement - LEIDEN, THE NETHERLANDS and SEATTLE, WA, June 17, 2010 - more> Press Release ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps™ and Appoints New Chief Medical Officer - LEIDEN, THE NETHERLANDS and SEATTLE, WA, March 9, 2010 - more> Press Release ProFibrix obtains government loan of up to EUR 5 million (~US$7.4 million) LEIDEN, THE NETHERLANDS and SEATTLE, WA, January 7, 2010 -more> Press Release ProFibrix raises US $11 million (EUR 8 million) in series B financing LEIDEN, THE NETHERLANDS and SEATTLE, WA, August 24, 2009 - more> Press Release ProFibrix initiates Phase II clinical trial of its lead topical hemostat product Fibrocaps™ SEATTLE, WA, and LEIDEN, THE NETHERLANDS, June 18, 2009 - more> Press Release ProFibrix Steps Up Recombinant Fibrinogen Program with PER.C6® License from Crucell Commercial License to Accelerate Development of New Hemostasis Breakthrough Products more> Press Release ProFibrix expands Management team and opens US subsidiary New COO brings financing and product development experience in the US.more> Press Release ProFibrix raises up to $ 11 million (€ 8.5 million) Series A financing led by Index Ventures Leiden, The Netherlands, 26 March2007. ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has closed a Series A financing raising $ 11 Million. more>